BR9812046A - Compostos, processos para a preperação do composto e para tratar um paciente humano ou animal, composição farmacêutica, e, uso de um composto - Google Patents
Compostos, processos para a preperação do composto e para tratar um paciente humano ou animal, composição farmacêutica, e, uso de um compostoInfo
- Publication number
- BR9812046A BR9812046A BR9812046-8A BR9812046A BR9812046A BR 9812046 A BR9812046 A BR 9812046A BR 9812046 A BR9812046 A BR 9812046A BR 9812046 A BR9812046 A BR 9812046A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- compound
- compounds
- fluorine atoms
- treating
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 13
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000001153 fluoro group Chemical group F* 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 abstract 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 abstract 1
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
Abstract
"COMPOSTOS, PROCESSOS PARA A PREPARAçãO DO COMPOSTO E PARA TRATAR UM PACIENTE HUMANO OU ANIMAL, COMPOSIçãO FARMACêUTICA, E, USO DE UM COMPOSTO". A invenção fornece os compostos da fórmula (I) e seus derivados farmaceuticamente aceitáveis em que: R^ 0^ é halogênio, alquila C~ 1-6~, alcóxi C~ 1-6~ substituído por um ou mais átomos de flúor ou O(CH~ 2~)~ n~NR^ 4^R^ 5^; R¹ e R² são independentemente selecionados de H, alquila C~ 1-6~, alquila C~ 1-6~ substituída por um ou mais átomos de flúor, alcóxi C~ 1-6~, hidroxialquila C~ 1-6~, S alquila C~ 1-6~, C(O)H, C(O) alquila C~ 1-6~, alquilsulfonia C~ 1-6~, alcóxi C~ 1-6~ substituído por um ou mais átomos de flúor, O(CH~ 2~)~ n~CO~ 2~ alquila C~ 1-6~, O(CH~ 2~)~ n~S alquila C~ 1-6~, (CH~ 2~)~ n~NR^ 4^R^ 5^, (CH~ 2~)~ n~S alquila C~ 1-6~ ou C(O)NR^ 4^R^ 5^, com a condição de que quando R^ 0^ está na posição 4 e é halogênio, pelo menos um R¹ e R² é alquilsulfonila C~ 1-6~, alcóxi C~ 1-6~ substituído por um ou mais átomos de flúor, O(CH~ 2~)~ n~CO~ 2~ alquila C~ 1-6~, O(CH~ 2-~)~ n~S alquila C~ 1-6~, (CH~ 2~)~ n~NR^ 4^R^ 5^, (CH~ 2~)~ n~S alquila C~ 1-6~ ou C(O)NR^ 4^R^ 5^, R³ é alquila C~ 1-6~ ou NH~ 2~; R^ 4^ e R^ 5^ são independentemente selecionados de H ou alquila C~ 1-6~ ou, junto com o átomo de nitrogênio ao qual estão ligados formam um anel saturado de 4 a 8 membros; n é de 1 a 4. Os compostos da fórmula (I) são inibidores potentes e seletivos da COX-2 e são de uso no tratamento da dor, febre, inflamação de uma variedade de condições e de doenças.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9718792.6A GB9718792D0 (en) | 1997-09-05 | 1997-09-05 | Chemical compounds |
| GBGB9727116.7A GB9727116D0 (en) | 1997-12-23 | 1997-12-23 | Chemical compounds |
| PCT/EP1998/005558 WO1999012930A1 (en) | 1997-09-05 | 1998-09-03 | 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their prepa ration and their use as cyclooxygenase 2 (cox-2) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9812046A true BR9812046A (pt) | 2000-09-26 |
Family
ID=26312181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9812046-8A BR9812046A (pt) | 1997-09-05 | 1998-09-03 | Compostos, processos para a preperação do composto e para tratar um paciente humano ou animal, composição farmacêutica, e, uso de um composto |
Country Status (28)
| Country | Link |
|---|---|
| US (4) | US6451794B1 (pt) |
| EP (3) | EP1369421B1 (pt) |
| KR (1) | KR100382619B1 (pt) |
| CN (1) | CN1155600C (pt) |
| AP (1) | AP1354A (pt) |
| AT (3) | ATE317845T1 (pt) |
| AU (1) | AU744997B2 (pt) |
| BG (1) | BG64420B1 (pt) |
| BR (1) | BR9812046A (pt) |
| CA (1) | CA2303152A1 (pt) |
| DE (3) | DE69833464T2 (pt) |
| DK (1) | DK1032575T3 (pt) |
| EA (1) | EA002775B1 (pt) |
| EE (1) | EE04617B1 (pt) |
| ES (3) | ES2231757T3 (pt) |
| HR (1) | HRP20000122B1 (pt) |
| HU (1) | HUP0003644A3 (pt) |
| IL (1) | IL134688A (pt) |
| IS (1) | IS5389A (pt) |
| NO (1) | NO315559B1 (pt) |
| NZ (1) | NZ502985A (pt) |
| PL (1) | PL194557B1 (pt) |
| PT (1) | PT1032575E (pt) |
| SK (1) | SK283922B6 (pt) |
| TR (1) | TR200000595T2 (pt) |
| TW (1) | TW570922B (pt) |
| WO (1) | WO1999012930A1 (pt) |
| YU (1) | YU11900A (pt) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2231757T3 (es) | 1997-09-05 | 2005-05-16 | Glaxo Group Limited | Composiciones farmaceutica que comprenden derivados de 2,3-diaril-pirazolo (1,5-b) piridazina. |
| BR9915011A (pt) * | 1998-11-03 | 2001-08-07 | Glaxo Group Ltd | Compostos, método para a preparação dos mesmos, composição farmacêutica, métodos de tratamento de um indivìduo humano ou animal sofrendo de uma condição que é mediada pela inibição seletiva de cox-2 e sofrendo de um distúrbio inflamatório, e, uso de um composto |
| US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| EP1157025B1 (en) | 1999-02-27 | 2004-03-10 | Glaxo Group Limited | Pyrazolopyridines |
| GB9929039D0 (en) * | 1999-12-08 | 2000-02-02 | Glaxo Group Ltd | Medicaments |
| GB9930358D0 (en) * | 1999-12-22 | 2000-02-09 | Glaxo Group Ltd | Process for the preparation of chemical compounds |
| NZ519781A (en) | 1999-12-23 | 2004-04-30 | Nitromed Inc | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| GB0002312D0 (en) * | 2000-02-01 | 2000-03-22 | Glaxo Group Ltd | Medicaments |
| CA2415577C (en) | 2000-07-20 | 2010-10-19 | Lauras As | Use of cox-2 inhibitors for preventing immunodeficiency |
| PE20020506A1 (es) * | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
| GB0021494D0 (en) * | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
| GB0025449D0 (en) * | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
| US6919352B2 (en) | 2000-12-15 | 2005-07-19 | Smithkline Beecham Corporation | Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds |
| ES2243579T3 (es) | 2000-12-15 | 2005-12-01 | Glaxo Group Ltd | Derivados de pirazolopirideno. |
| DE60201074T2 (de) | 2001-03-08 | 2005-09-15 | Smithkline Beecham Corp. | Pyrazolopyridinderivate |
| JP4237497B2 (ja) | 2001-03-30 | 2009-03-11 | スミスクライン ビーチャム コーポレーション | ピラゾロピリジン類、その調製方法及びその治療用化合物としての使用 |
| WO2002083672A1 (en) | 2001-04-10 | 2002-10-24 | Smithkline Beecham Corporation | Antiviral pyrazolopyridine compounds |
| US6756498B2 (en) | 2001-04-27 | 2004-06-29 | Smithkline Beecham Corporation | Process for the preparation of chemical compounds |
| WO2002088124A2 (en) | 2001-04-27 | 2002-11-07 | Smithkline Beecham Corporation | Pyrazolo'1,5-a!pyridine derivatives |
| GB0112802D0 (en) * | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
| GB0112810D0 (en) * | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
| HUP0400266A2 (hu) | 2001-06-21 | 2004-08-30 | Smithkline Beecham Corp. | Imidazo[1,2-a]piridin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk herpeszvírus-fertőzések megelőzésére vagy kezelésére |
| WO2003031446A1 (en) | 2001-10-05 | 2003-04-17 | Smithkline Beecham Corporation | Imidazo-pyridine derivatives for use in the treatment of herpes viral infection |
| GB0124936D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124938D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124941D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124939D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124931D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124934D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124932D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124933D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| DE60222465T2 (de) | 2001-12-11 | 2008-06-05 | Smithkline Beecham Corp. | Pyrazolopyridin-derivate als antiherpesmittel |
| JP2005524609A (ja) | 2001-12-17 | 2005-08-18 | スミスクライン ビーチャム コーポレーション | ピラゾロピリダジン誘導体 |
| KR100840907B1 (ko) * | 2001-12-28 | 2008-06-24 | 씨제이제일제당 (주) | 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난바이피리디닐 유도체 |
| KR100686537B1 (ko) | 2001-12-28 | 2007-02-27 | 씨제이 주식회사 | 사이클로옥시게나제-2 의 저해제로서 선택성이 뛰어난디아릴 1,2,4-트리아졸 유도체 |
| DK1474395T3 (da) * | 2002-02-12 | 2008-02-11 | Smithkline Beecham Corp | Nicotinamidderivater, der er nyttige som p38-inhibitorer |
| GB0206200D0 (en) * | 2002-03-15 | 2002-05-01 | Glaxo Group Ltd | Pharmaceutical compositions |
| GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
| US7235560B2 (en) * | 2002-08-19 | 2007-06-26 | Glaxo Group Limited | Pyrimidine derivative as selective COX-2 inhibitors |
| UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
| GB0221443D0 (en) | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
| EP1546148A1 (en) | 2002-10-03 | 2005-06-29 | SmithKline Beecham Corporation | Therapeutic compounds based on pyrazolopyridine derivatives |
| US20040147581A1 (en) * | 2002-11-18 | 2004-07-29 | Pharmacia Corporation | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy |
| GB0227443D0 (en) * | 2002-11-25 | 2002-12-31 | Glaxo Group Ltd | Pyrimidine derivatives |
| ES2214130B1 (es) * | 2003-02-13 | 2005-12-01 | Almirall Prodesfarma, S.A. | 2-3'-bipiridinas. |
| ES2214129B1 (es) * | 2003-02-13 | 2005-12-01 | Almirall Prodesfarma, S.A. | 3-fenilfuran-2-onas. |
| ES2213485B1 (es) * | 2003-02-13 | 2005-12-16 | Almirall Prodesfarma, S.A. | Derivados de la 2-fenilpiran-4-ona. |
| US20040220155A1 (en) * | 2003-03-28 | 2004-11-04 | Pharmacia Corporation | Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith |
| GB0308201D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| GB0308185D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| GB0308186D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| DK1534305T3 (da) | 2003-05-07 | 2007-02-05 | Osteologix As | Behandling af brusk-/knoglelidelser med vandoplöselige strontiumsalte |
| WO2005009342A2 (en) * | 2003-07-16 | 2005-02-03 | Pharmacia Corporation | Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith |
| GB0318814D0 (en) * | 2003-08-11 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
| GB0319037D0 (en) * | 2003-08-13 | 2003-09-17 | Glaxo Group Ltd | 7-Azaindole Derivatives |
| US20050119262A1 (en) * | 2003-08-21 | 2005-06-02 | Pharmacia Corporation | Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent |
| US20050113409A1 (en) * | 2003-09-03 | 2005-05-26 | Pharmacia Corporation | Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith |
| GB0402143D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| US20080051416A1 (en) * | 2004-10-05 | 2008-02-28 | Smithkline Beecham Corporation | Novel Compounds |
| EA200801909A1 (ru) | 2004-12-23 | 2009-06-30 | Глэксо Груп Лимитед | Соединения пиридина для лечения заболеваний, опосредованных действием простагландина |
| EP1827468B1 (en) * | 2004-12-23 | 2012-08-22 | Curaxis Pharmaceutical Corporation | Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease |
| US20060269579A1 (en) * | 2005-05-25 | 2006-11-30 | Musculoskeletal Research Llc | Compositions for treating osteoarthritis |
| US7767710B2 (en) | 2005-05-25 | 2010-08-03 | Calosyn Pharma, Inc. | Method for treating osteoarthritis |
| GB0512429D0 (en) * | 2005-06-17 | 2005-07-27 | Smithkline Beecham Corp | Novel compound |
| GB0704407D0 (en) | 2007-03-07 | 2007-04-18 | Glaxo Group Ltd | Compounds |
| US7943658B2 (en) | 2007-07-23 | 2011-05-17 | Bristol-Myers Squibb Company | Indole indane amide compounds useful as CB2 agonists and method |
| WO2009042854A1 (en) * | 2007-09-26 | 2009-04-02 | Musculoskeletal Research Llc | Ion-channel regulator compositions and methods of using same |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| WO2011012622A1 (en) | 2009-07-30 | 2011-02-03 | Glaxo Group Limited | Benzoxazinone derivatives for the treatment of glytl mediated disorders |
| WO2011023753A1 (en) | 2009-08-27 | 2011-03-03 | Glaxo Group Limited | Benzoxazine derivatives as glycine transport inhibitors |
| GB201000685D0 (en) | 2010-01-15 | 2010-03-03 | Glaxo Group Ltd | Novel compounds |
| GB201007789D0 (en) | 2010-05-10 | 2010-06-23 | Glaxo Group Ltd | Novel Compound |
| GB201007791D0 (en) | 2010-05-10 | 2010-06-23 | Glaxo Group Ltd | Novel compounds |
| US9115132B2 (en) | 2010-07-09 | 2015-08-25 | Convergence Pharmaceuticals Limited | Tetrazole compounds as calcium channel blockers |
| US8933132B2 (en) | 2011-01-19 | 2015-01-13 | Convergence Pharmaceuticals Limited | Tricyclic substituted benzenesulfonamide piperazine derivatives as CAV2.2 calcium channel blockers |
| GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201417497D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
| GB201417499D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
| GB201417500D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
| US11096924B2 (en) | 2016-09-07 | 2021-08-24 | Trustees Of Tufts College | Combination therapies using immuno-dash inhibitors and PGE2 antagonists |
| WO2022195579A1 (en) | 2021-03-15 | 2022-09-22 | Saul Yedgar | Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases |
| CN115611901B (zh) * | 2021-07-16 | 2024-04-30 | 华南理工大学 | 一种氮杂䓬类化合物或其药学上可接受的盐及其制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5002941A (en) | 1985-12-12 | 1991-03-26 | Smithkline Beecham Corporation | Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors |
| US4925849A (en) | 1987-06-15 | 1990-05-15 | Fujisawa Pharmaceutical Company, Ltd. | Pharmaceutically useful pyrazolopyridines |
| US5155114A (en) | 1989-01-23 | 1992-10-13 | Fujisawa Pharmaceutical Company, Ltd. | Method of treatment using pyrazolopyridine compound |
| GB8901423D0 (en) | 1989-01-23 | 1989-03-15 | Fujisawa Pharmaceutical Co | Pyrazolopyridine compound and processes for preparation thereof |
| WO1991000092A1 (en) | 1989-06-13 | 1991-01-10 | Smithkline Beecham Corporation | Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages |
| AU622330B2 (en) | 1989-06-23 | 1992-04-02 | Takeda Chemical Industries Ltd. | Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides |
| IL95031A (en) * | 1989-07-18 | 2007-03-08 | Amgen Inc | A method of producing a recombinant human necrotic factor absorber |
| KR930700104A (ko) | 1990-06-12 | 1993-03-13 | 원본미기재 | 5-리프옥시게나제 및 사이클로옥시게나제 경로 개재된 질병의 억제 |
| GB9015764D0 (en) | 1990-07-18 | 1990-09-05 | Fujisawa Pharmaceutical Co | Pyrazolopyridine compound and processes for preparation thereof |
| FR2699077B1 (fr) * | 1992-12-16 | 1995-01-13 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes. |
| US5300478A (en) | 1993-01-28 | 1994-04-05 | Zeneca Limited | Substituted fused pyrazolo compounds |
| US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| CA2180651A1 (en) | 1994-01-10 | 1995-07-13 | Yves Ducharme | Phenyl heterocycles as cox-2 inhibitors |
| US5521213A (en) * | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
| US5552422A (en) * | 1995-01-11 | 1996-09-03 | Merck Frosst Canada, Inc. | Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents |
| CZ313397A3 (cs) | 1995-04-04 | 1998-03-18 | Glaxo Group Limited | Imidazo/1,2a/pyridinové deriváty, způsob jejich výroby a farmaceutický prostředek s jejich obsahem |
| US6136839A (en) | 1995-06-12 | 2000-10-24 | G. D. Searle & Co. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor |
| CA2224563A1 (en) | 1995-06-12 | 1996-12-27 | G.D. Searle & Co. | Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations |
| US5700816A (en) | 1995-06-12 | 1997-12-23 | Isakson; Peter C. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
| GB9513508D0 (en) * | 1995-07-03 | 1995-09-06 | Fujisawa Pharmaceutical Co | Quinazoline derivatives |
| ES2231757T3 (es) * | 1997-09-05 | 2005-05-16 | Glaxo Group Limited | Composiciones farmaceutica que comprenden derivados de 2,3-diaril-pirazolo (1,5-b) piridazina. |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
-
1998
- 1998-09-03 ES ES03077298T patent/ES2231757T3/es not_active Expired - Lifetime
- 1998-09-03 YU YU11900A patent/YU11900A/sh unknown
- 1998-09-03 CN CNB988108763A patent/CN1155600C/zh not_active Expired - Fee Related
- 1998-09-03 TR TR2000/00595T patent/TR200000595T2/xx unknown
- 1998-09-03 EP EP03077298A patent/EP1369421B1/en not_active Expired - Lifetime
- 1998-09-03 WO PCT/EP1998/005558 patent/WO1999012930A1/en not_active Application Discontinuation
- 1998-09-03 DE DE69833464T patent/DE69833464T2/de not_active Expired - Lifetime
- 1998-09-03 EA EA200000188A patent/EA002775B1/ru not_active IP Right Cessation
- 1998-09-03 AT AT04025990T patent/ATE317845T1/de not_active IP Right Cessation
- 1998-09-03 AP APAP/P/2000/001753A patent/AP1354A/en active
- 1998-09-03 DK DK98947502T patent/DK1032575T3/da active
- 1998-09-03 US US09/508,029 patent/US6451794B1/en not_active Expired - Fee Related
- 1998-09-03 IL IL13468898A patent/IL134688A/xx not_active IP Right Cessation
- 1998-09-03 NZ NZ502985A patent/NZ502985A/en unknown
- 1998-09-03 AT AT98947502T patent/ATE245649T1/de not_active IP Right Cessation
- 1998-09-03 HU HU0003644A patent/HUP0003644A3/hu unknown
- 1998-09-03 KR KR10-2000-7002322A patent/KR100382619B1/ko not_active IP Right Cessation
- 1998-09-03 AU AU94395/98A patent/AU744997B2/en not_active Ceased
- 1998-09-03 ES ES04025990T patent/ES2256817T3/es not_active Expired - Lifetime
- 1998-09-03 DE DE69816651T patent/DE69816651T2/de not_active Expired - Lifetime
- 1998-09-03 PT PT98947502T patent/PT1032575E/pt unknown
- 1998-09-03 DE DE69827419T patent/DE69827419T2/de not_active Expired - Lifetime
- 1998-09-03 PL PL98339059A patent/PL194557B1/pl unknown
- 1998-09-03 EP EP04025990A patent/EP1510519B1/en not_active Expired - Lifetime
- 1998-09-03 EP EP98947502A patent/EP1032575B1/en not_active Expired - Lifetime
- 1998-09-03 AT AT03077298T patent/ATE281458T1/de not_active IP Right Cessation
- 1998-09-03 SK SK294-2000A patent/SK283922B6/sk unknown
- 1998-09-03 CA CA002303152A patent/CA2303152A1/en not_active Abandoned
- 1998-09-03 BR BR9812046-8A patent/BR9812046A/pt not_active Application Discontinuation
- 1998-09-03 ES ES98947502T patent/ES2203985T3/es not_active Expired - Lifetime
- 1998-09-03 EE EEP200000113A patent/EE04617B1/xx not_active IP Right Cessation
-
1999
- 1999-02-19 TW TW088102423A patent/TW570922B/zh not_active IP Right Cessation
-
2000
- 2000-02-25 IS IS5389A patent/IS5389A/is unknown
- 2000-03-03 HR HR960321A patent/HRP20000122B1/xx not_active IP Right Cessation
- 2000-03-03 NO NO20001102A patent/NO315559B1/no unknown
- 2000-03-28 BG BG104279A patent/BG64420B1/bg unknown
-
2002
- 2002-08-05 US US10/212,514 patent/US6831097B2/en not_active Expired - Fee Related
- 2002-08-05 US US10/212,513 patent/US6861429B2/en not_active Expired - Fee Related
-
2004
- 2004-10-27 US US10/974,893 patent/US20050113377A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9812046A (pt) | Compostos, processos para a preperação do composto e para tratar um paciente humano ou animal, composição farmacêutica, e, uso de um composto | |
| BR9915011A (pt) | Compostos, método para a preparação dos mesmos, composição farmacêutica, métodos de tratamento de um indivìduo humano ou animal sofrendo de uma condição que é mediada pela inibição seletiva de cox-2 e sofrendo de um distúrbio inflamatório, e, uso de um composto | |
| NO173139C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-aminopyrimidinonderivater | |
| BR0113448A (pt) | Composto da fórmula ou um sal ou solvato deste ou um derivado destes fisiologicamente funcional, composição farmacêutica, uso do composto ou de um sal ou solvato deste ou de um derivado destes fisiologicamente funcional, e , métodos para tratar uma condição ou estado de doença mediados pela p38 quinase ou mediados pelas citoquinas, e mediados pela jnk quinase ou mediados pelas citoquinas, e ,para tratar duas ou mais condições ou doenças independentemente mediadas pela atividade da p38 e da jnk quinase | |
| ES2173074T3 (es) | Derivados de xantina, procedimiento para su preparacion y su uso farmaceutico. | |
| BR0015193A (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma condição associada com trasmissão reduzida de nicotina, para tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para tratamento ou profilaxia de doenças ou condições humanas | |
| DK9185D0 (da) | Dihydropyridazinonderivater og fremgangsmaade til fremstilling deraf | |
| NO171365C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolderivater | |
| BR0215151A (pt) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| BR0317680A (pt) | Composto, composição farmacêutica, uso de um composto, ou de um sal farmaceuticamente aceitável do mesmo, método de tratamento de um ser humano, e, processo para a preparação de um composto | |
| MX9203417A (es) | Compuestos de diarilo antiateroescleroticos. | |
| NO20040589L (no) | Arylsulfonylderivater med 5-HT6 reseptor affinitet. | |
| BR9807950A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto | |
| DK0570294T3 (da) | 2-formylpyridinthiosemicarbazonderivater, deres fremstilling og deres anvendelse som antitumormiddel | |
| EE04496B1 (et) | Tetrahüdro-gamma-karboliinid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad kompositsioonid | |
| ES2051834T3 (es) | El uso de tetrahidrobenzeno(c,d)indol-6 carboxamidas para la preparacion de un medicamento para el tratamiento de la ansiedad. | |
| ES524680A0 (es) | Procedimiento de obtencion de nuevos compuestos derivados de la difenil-metilen-etilamina. | |
| MD1560F2 (en) | Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses. | |
| DK122191A (da) | Benzimidazolderivat og fysiologisk acceptable salte heraf samt fremgangsmaade til fremstilling af samme | |
| DK0516350T3 (da) | 2-hydroxy-2-phenylethylamin-derivater som beta-3-adrenoceptoragonister | |
| DK148288A (da) | N-phenethylaminoalkyl-benzamid-forbindelser, deres anvendelse til fremstilling af antiarrhythmia-laegemidler og farmaceutiske praeparater indeholdende forbindelserne | |
| DK0885004T3 (da) | Anvendelse af 4-phenyl-3,6-dihydro-2H-pyridyl-derivater som NMDA-receptor-undertypeblokkere | |
| SE8603589L (sv) | Metylendioxifenantren- och stilbenderivat | |
| BR9808546A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições do ser humano, tratar ou reduzir o risco de doença inflamatória e o risco da dor em uma pessoa que sofre, ou em risco, da dita doença e para a preparação do composto | |
| DE3783821D1 (de) | Tetracyclische indolderivate. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |